UAE clears Lilly pill for obesity care

Patients in the UAE are set to gain access from May to a new once-daily obesity treatment in tablet form after the Emirates Drug Establishment approved Eli Lilly’s Foundayo, known chemically as orforglipron, marking what officials described as the second national registration for the medicine and widening treatment choices beyond injections. The decision places the UAE among the earliest markets to back a new generation of oral weight-management drugs aimed at chronic obesity.

The approval gives doctors and eligible patients a needle-free option in a market where injectable GLP-1 medicines have dominated demand. Foundayo is a glucagon-like peptide-1 receptor agonist designed for daily oral use and, unlike some rival therapies, can be taken without food or water timing restrictions. That convenience is central to Lilly’s commercial pitch and to the policy message from UAE regulators, who framed the move as part of a broader push to accelerate access to advanced therapies and improve the patient experience.

Dr Fatima Al Kaabi, director-general of the Emirates Drug Establishment, said the approval underlined the country’s commitment to adopting newer pharmaceutical innovations for people living with obesity. The regulator also linked the decision to the burden obesity places on public health, noting its association with more than 200 diseases and complications, including type 2 diabetes, hypertension and multiple cancers. Roberta Marinelli, president and general manager for Eli Lilly’s META Hub, said the oral treatment would broaden disease-management options for eligible patients in the UAE.

The UAE move comes just days after the United States approved Foundayo on April 1, 2026, for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related medical condition. Reuters reported that Lilly planned a U. S. launch from April 6, while the company has said regulatory filings are under way in more than 40 countries. That timeline helps explain why the UAE approval is being watched closely by industry analysts: it suggests some Gulf regulators are willing to move quickly on high-profile metabolic drugs as competition intensifies between Lilly and Novo Nordisk.

Clinical evidence has been one of the main drivers behind that regulatory momentum. In the phase 3 ATTAIN-1 trial published in the New England Journal of Medicine, adults with obesity who received orforglipron for 72 weeks achieved significantly greater weight reduction than those given placebo, with the highest-dose group showing mean body-weight reduction of 11.2% under the treatment-regimen analysis. An efficacy analysis reported larger losses, around 12.4%. A separate phase 3 trial in adults with obesity and type 2 diabetes, published in The Lancet, also found clinically meaningful reductions in body weight against placebo.

The appeal of oral GLP-1 drugs goes beyond convenience. Tablets are easier to store, transport and scale than injectable biologics, an advantage that could matter in markets seeking wider access and more resilient supply chains. Lilly has emphasised that orforglipron is a small-molecule, non-peptide medicine, which differs from peptide-based injectable products and may simplify manufacturing and distribution. Analysts quoted by Reuters expect pills to account for a meaningful share of the obesity-drug market by the end of the decade, even if injections remain more powerful for some patients.

Still, enthusiasm is being tempered by medical and commercial realities. Foundayo’s label in the United States carries warnings consistent with the GLP-1 class, including a boxed warning related to thyroid C-cell tumours, and gastrointestinal side effects remain common. Specialists have also cautioned against simplistic comparisons between products because there are no direct obesity head-to-head trials between Foundayo and every competing oral therapy, and injectable medicines such as tirzepatide and semaglutide have generally produced greater average weight loss in separate studies.